Metropolis Healthcare Ltd
Metropolis Healthcare Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Organic revenue growth target for FY '26 is 12% to 13%, with ambition to hit the higher end of the range. The company aims for mid- to high single-digit patient volume growth (7% to 8%) in the near future, supported by ongoing programs.
From Metropolis Healthcare Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Organic revenue growth target for FY '26 is 12% to 13%, with ambition to hit the higher end of the range.
- Q3 delivered a strong 15% organic revenue growth; the company expects improved top-line performance in Q4.
- Patient volume growth is targeted at 7% to 8% in the near future, supported by early success in growth programs.
- Test volume grew 8% organically in Q3, reflecting expanding contribution from wellness and specialty segments.
- Expansion in Tier 2 and Tier 3 cities through franchise channels is expected to drive consistent volume growth.
- Growth in specialty and advanced diagnostic tests, including genomics, is anticipated to be a key driver over the next 10 years.
2 more points from Metropolis Healthcare Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Metropolis Healthcare Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capex guidance for the 9-month period is approximately INR 40 crores; expected full-year capex around INR 60 crores (Page 15).
- Capex primarily directed towards strengthening and expanding the pan-India lab and collection center network, upgrading IT systems, processes, and scaling up high-end equipment for advanced and super-specialty test capabilities (Page 9).
- Aspirational target to improve collection centers (CC) per lab ratio from ~20-22 to around 30 centers per lab; timeline not fixed, gradual progression focused on consolidation and expansion (Page 17).
2 more points from Metropolis Healthcare Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Metropolis Healthcare Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Metropolis Healthcare Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Metropolis Healthcare Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹425 Cr, net profit ₹51 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Metropolis Healt's management said in earlier quarters
- Q2 FY26 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q1 FY26 earnings call →
- Q4 FY25 earnings call →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
Others in Healthcare Services this season
- Vijaya Diagnostic Centre Ltd (Q3 FY26)
FY '27 capex of INR 100-120 crores planned, supporting network expansion (Page 5). Key concall takeaways from Vijaya Diagnost.'s Q3 FY26 earnings call — and…
- Chandan Healthcare Ltd (Q3 FY26)
The company plans to open 100 new labs within three years, with an overall capex of INR100 crores for this expansion. Key concall takeaways from Chandan…
- Rainbow Childrens Medicare Ltd (Q3 FY26)
Revenue growth for the quarter was 12% YoY; 9% for the first 9 months of the financial year. Key concall takeaways from Rainbow Childrens Medicare Ltd's Q3…
- Krsnaa Diagnostics Ltd (Q3 FY26)
Retail segment showing strong momentum, with retail revenue growing nearly 8x YoY in Q3 FY '26, contributing 8% of total revenue; network expanded to over…
Arthneeti Pro · Annual
Metropolis Healthcare Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Metropolis Healthcare Ltd Q3 FY26 results?
Organic revenue growth target for FY '26 is 12% to 13%, with ambition to hit the higher end of the range. The company aims for mid- to high single-digit patient volume growth (7% to 8%) in the near future, supported by ongoing programs.
What is Metropolis Healthcare Ltd share price analysis?
Metropolis Healthcare Ltd currently shows a neutral. The stock trades at a P/E of 54.4 with a market cap of ₹11,313 Cr. Investors should review the full earnings analysis for detailed insights.
Is Metropolis Healthcare Ltd planning capital expenditure?
Capex guidance for the 9-month period is approximately INR 40 crores; expected full-year capex around INR 60 crores (Page 15).
Keep Metropolis Healthcare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.